APR-246 exhibits anti-leukemic activity and synergism with conventional chemotherapeutic drugs in acute myeloid leukemia cells

European Journal of Haematology

Volumn 86, Issue 3, 2011, Pages 206-215

  Ali, Dina ^a   Jönsson Videsäter, Kerstin ^a   Deneberg, Stefan ^a   Bengtzén, Sofia ^a   Nahi, Hareth ^a   Paul, Christer ^a   Lehmann, Sören ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Acute myeloid leukemia; Apoptosis; APR 246; Synergism; TP53

Indexed keywords

ANTILEUKEMIC AGENT; APR 246; ARABINE; CASPASE 3; CYTARABINE; DAUNORUBICIN; FLUDARABINE; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P14; PROTEIN P53; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL SURVIVAL; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CYTOTOXICITY; DRUG POTENTIATION; FEMALE; GENE MUTATION; HUMAN; HUMAN CELL; KARYOTYPE; LEUKEMIA CELL; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TREATMENT RESPONSE; UPREGULATION;

ANTINEOPLASTIC AGENTS; AZA COMPOUNDS; BASE SEQUENCE; BCL-2-ASSOCIATED X PROTEIN; BICYCLO COMPOUNDS, HETEROCYCLIC; CYTARABINE; DAUNORUBICIN; DNA PRIMERS; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; FEMALE; GENE EXPRESSION; GENES, P53; HUMANS; KARYOTYPING; LEUKEMIA, MYELOID, ACUTE; MALE; MUTATION; PROTO-ONCOGENE PROTEINS C-BCL-2; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P14ARF; VIDARABINE;

EID: 79951646356     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2010.01557.x     Document Type: Article

References (43)

1. Olivier M, Eeles R, Hollstein M, Khan MA, Harris CC, Hainaut P. The IARC TP53 database: new online mutation analysis and recommendations to users. Hum Mutat 2002;19:607-14.
2. Haferlach C, Dicker F, Herholz H, Schnittger S, Kern W, Haferlach T. Mutations of the TP53 gene in acute myeloid leukemia are strongly associated with a complex aberrant karyotype. Leukemia 2008;22:1539-41.
3. Nahi H, Selivanova G, Lehmann S, Möllgård L, Bengtzen S, Concha H, Svensson A, Wiman KG, Merup M, Paul C. Mutated and non-mutated TP53 as targets in the treatment of leukaemia. Br J Haematol 2008;141:445-53.
4. Bykov VJ, Issaeva N, Shilov A, Hultcrantz M, Pugacheva E, Chumakov P, Bergman J, Wiman KG, Selivanova G. Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound. Nat Med 2002;8:282-8.
5. Zache N, Lambert JM, Wiman KG, Bykov VJ. PRIMA-1MET inhibits growth of mouse tumors carrying mutant p53. Cell Oncol 2008;30:411-8.
6. Nahi H, Merup M, Lehmann S, Bengtzen S, Möllgård L, Selivanova G, Wiman KG, Paul C. PRIMA-1 induces apoptosis in acute myeloid leukaemia cells with p53 gene deletion. Br J Haematol 2006;132:p.
7. Sherr CJ. Tumor surveillance via the ARF-p53 pathway. Genes Dev 1998;12:2984-91.
8. Andersson BS, Bergerheim US, Collins VP, et al. KBM-3, an in vitro model of human acute myelomonocytic leukemia. Exp Hematol 1992;20:361-7.
9. Fenaux P, Preudhomme C, Quiquandon I, Jonveaux P, Lai JL, Vanrumbeke M, Loucheux-Lefebvre MH, Bauters F, Berger R, Kerckaert JP. Mutations of the P53 gene in acute myeloid leukaemia. Br J Haematol 1992;80:178-83.
10. Ishikawa Y, Kiyoi H, Tsujimura A, Miyawaki S, Miyazaki Y, Kuriyama K, Tomonaga M, Naoe T. Comprehensive analysis of cooperative gene mutations between class I and class II in de novo acute myeloid leukemia. Eur J Haematol 2009;83:90-8.
11. Möllgård L, Tidefelt U, Sundman-Engberg B, Löfgren C, Paul C. In vitro chemosensitivity testing in acute non lymphocytic leukemia using the bioluminescence ATP assay. Leuk Res 2000;24:445-52.
12. Haglund U, Juliusson G, Stellan B, Gahrton G. Hairy cell leukemia is characterized by clonal chromosome abnormalities clustered to specific regions. Blood 1994;83:2637-45.
13. Cree IA, Kurbacher CM. ATP-based tumor chemosensitivity testing: assisting new agent development. Anticancer Drugs 1999;10:431-5.
14. Kangas L, Gronroos M, Nieminen AL. Bioluminescence of cellular ATP: a new method for evaluating cytotoxic agents in vitro. Med Biol 1984;62:338-43.
15. Rhedin AS, Tidefelt U, Jönsson K, Lundin A, Paul C. Comparison of a bioluminescence assay with differential staining cytotoxicity for cytostatic drug testing in vitro in human leukemic cells. Leuk Res 1993;17:271-6.
16. van Stijn A, Kok A, van der Pol MA, Feller N, Roemen GM, Westra AH, Ossenkoppele GJ, Schuurhuis GJ. A flow cytometric method to detect apoptosis-related protein expression in minimal residual disease in acute myeloid leukemia. Leukemia, 2003;17:780-6.
17. Paul E, Uggla B, Deneberg S, Bengtzen S, Hermansson M, Dahlman I, Rosenquist R, Wiman KG, Nahi H. Low p14ARF expression in de novo acute myeloid leukemia with normal karyotype is associated with poor survival. Leuk Lymphoma 2009;50:1512-8.
18. Fransen K, Klintenas M, Osterstrom A, Dimberg J, Monstein HJ, Söderkvist P. Mutation analysis of the BRAF, ARAF and RAF-1 genes in human colorectal adenocarcinomas. Carcinogenesis 2004;25:527-33.
19. Möllgård L, Deneberg S, Nahi H, Bengtzen S, Jönsson-Videsäter K, Fioretos T, Andersson A, Paul C, Lehmann S. The FLT3 inhibitor PKC412 in combination with cytostatic drugs in vitro in acute myeloid leukemia. Cancer Chemother Pharmacol 2008;62:439-48.
20. Lepri E, Barzi A, Menconi E, Portuesi MG, Liberati M. In vitro synergistic activity of PDN-IFN alpha and NM + IFN alpha combinations on fresh bone-marrow samples from multiple myeloma patients. Hematol Oncol 1991;9:79-86.
21. Lambert JM, Gorzov P, Veprintsev DB, Soderqvist M, Segerback D, Bergman J, Fersht AR, Hainaut P, Wiman KG, Bykov VJ. PRIMA-1 reactivates mutant p53 by covalent binding to the core domain. Cancer Cell 2009;15:376-88.
22. Campos L, Rouault JP, Sabido O, Oriol P, Roubi N, Vasselon C, Archimbaud E, Magaud JP, Guyotat D. High expression of bcl-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy. Blood 1993;81:3091-6.
23. Zhang XH, Yu HL, Xiao R, Xiang L, Li L, Ma WW, Zhang J, Chu JH. [Neurotoxicity of beta-amyloid peptide 31-35 and 25-35 to cultured rat cortical neurons]. Zhonghua Yu Fang Yi Xue Za Zhi 2009;43:1081-5.
24. Valeriote F, Lin H. Synergistic interaction of anticancer agents: a cellular perspective. Cancer Chemother Rep 1975;59:895-900.
25. Selivanova G, Wiman KG. Reactivation of mutant p53: molecular mechanisms and therapeutic potential. Oncogene 2007;26:2243-54.
26. Blandino G, Levine AJ, Oren M. Mutant p53 gain of function: differential effects of different p53 mutants on resistance of cultured cells to chemotherapy. Oncogene 1999;18:477-85.
27. Bossi G, Lapi E, Strano S, Rinaldo C, Blandino G, Sacchi A. Mutant p53 gain of function: reduction of tumor malignancy of human cancer cell lines through abrogation of mutant p53 expression. Oncogene 2006;25:304-9.
28. Sigal A, Rotter V. Oncogenic mutations of the p53 tumor suppressor: the demons of the guardian of the genome. Cancer Res 2000;60:6788-93.
29. Wiman KG. Restoration of wild-type p53 function in human tumors: strategies for efficient cancer therapy. Adv Cancer Res 2007;97:321-38.
30. Stuber G, Flaberg E, Petranyi G, Otvos R, Rokaeus N, Kashuba E, Wiman KG, Klein G, Szekely L. PRIMA-1MET induces nucleolar translocation of Epstein-Barr virus-encoded EBNA-5 protein. Mol Cancer 2009;8:23.
31. Wattel E, Preudhomme C, Hecquet B, Vanrumbeke M, Quesnel B, Dervite I, Morel P, Fenaux P. p53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies. Blood 1994;84:3148-57.
32. Schoch C, Kern W, Kohlmann A, Hiddemann W, Schnittger S, Haferlach T. Acute myeloid leukemia with a complex aberrant karyotype is a distinct biological entity characterized by genomic imbalances and a specific gene expression profile. Genes Chromosom Cancer 2005;43:227-38.
33. Zheng A, Castren K, Saily M, Savolainen ER, Koistinen P, Vahakangas K. p53 status of newly established acute myeloid leukaemia cell lines. Br J Cancer 1999;79:407-15.
34. Lambert JM, Moshfegh A, Hainaut P, Wiman KG, Bykov VJ. Mutant p53 reactivation by PRIMA-1MET induces multiple signaling pathways converging on apoptosis. Oncogene 2010;29:1329-38.
35. Lucken-Ardjomande S, Martinou JC. Regulation of Bcl-2 proteins and of the permeability of the outer mitochondrial membrane. C R Biol 2005;328:616-31.
36. Miyashita T, Reed JC. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 1995;80:293-9.
37. Del Poeta G, Venditti A, Del Principe MI, et al. Amount of spontaneous apoptosis detected by Bax/Bcl-2 ratio predicts outcome in acute myeloid leukemia (AML). Blood 2003;101:2125-31.
38. Prokop A, Wieder T, Sturm I, Essmann F, Seeger K, Wuchter C, Ludwig WD, Henze G, Dorken B, Daniel PT. Relapse in childhood acute lymphoblastic leukemia is associated with a decrease of the Bax/Bcl-2 ratio and loss of spontaneous caspase-3 processing in vivo. Leukemia 2000;14:1606-13.
39. Bothner B, Lewis WS, DiGiammarino EL, Weber JD, Bothner SJ, Kriwacki RW. Defining the molecular basis of Arf and Hdm2 interactions. J Mol Biol, 2001;314:263-77.
40. Weber JD, Kuo ML, Bothner B, DiGiammarino EL, Kriwacki RW, Roussel MF, Sherr CJ. Cooperative signals governing ARF-mdm2 interaction and nucleolar localization of the complex. Mol Cell Biol 2000;20:2517-28.
41. Oyan AM, Anensen N, Bo TH, Stordrange L, Jonassen I, Bruserud O, Kalland KH, Gjertsen BT. Genes of cell-cell interactions, chemotherapy detoxification and apoptosis are induced during chemotherapy of acute myeloid leukemia. BMC Cancer, 2009;9:77.
42. Chou TC, Otter GM, Sirotnak FM. Schedule-dependent synergism of taxol or taxotere with edatrexate against human breast cancer cells in vitro. Cancer Chemother Pharmacol 1996;37:222-8.
43. Nakano K, Vousden KH. PUMA, a novel proapoptotic gene, is induced by p53. Mol Cell 2001;7:683-94.